期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Pseudocirrhosis after the Use of Taxanes and Bevacizumab in Metastatic Breast Cancer: Case Reports
1
作者 Gabriel Lima Lopes Bruna Migliavacca Zucchetti +2 位作者 Juliana Florinda de Mendoca Rego Daniela de Freitas ricardo jose marques 《Journal of Pharmacy and Pharmacology》 2017年第3期158-163,共6页
Currently, multiple lines of cytotoxic chemotherapy for treatment of metastatic breast cancer are available, and Taxanes, used as monotherapy or in combination with anti-angiogenic drugs, such as Bevacizumab, are one ... Currently, multiple lines of cytotoxic chemotherapy for treatment of metastatic breast cancer are available, and Taxanes, used as monotherapy or in combination with anti-angiogenic drugs, such as Bevacizumab, are one of the most used schemes in clinical practice. These drugs have different side effects and the liver is one of the most affected organs. The objective of this paper is to report three cases of metastatic breast cancer with positive expression of hormone receptors and without amplification of HER-2 protein that were treated with Taxane and Bevacizumab, developed pseudocirrosis probably caused by these drugs and died due to liver failure. It can be drawn from the study that liver failure, as a pseudocirrhosis evolution, is an unusual but lethal event that may occur during the treatment of metastatic breast cancer with Taxanes and Bevacizumab. This warns the importance of diagnostic suspicion of this pathology. 展开更多
关键词 Breast cancer TAXANES BEVACIZUMAB Pseudocirrhosis liver failure.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部